NL-OMON29750尚未招募3 期
Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice. - RE3, REtain REmicade REsponse
Schering-Plough0 个研究点目标入组 36 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Subject has RA according to ACR criteria
- •Subject aged 18 years or more
- •Subject received the standard Remicad dosing schedule as per the EU label: 3mg/kg weeks 0, 2 and 6 followed by 1 or 2 intervals of 8 weeks.
- •DAS 28 worsening of at least 0.6 between the time of initial response and the next 8 weekly infusion and the resulting DAS28 value
排除标准
- •Remicade allergy
- •patient didn't show an initial response on Remicade (infliximab) during the induction period.
研究者
相似试验
进行中（未招募）
不适用
Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice. - Re3Adult subjects with a diagnosis of Rheumatoid Arthritis presenting with a disease flare after an initial response to infliximabMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2005-001889-13-SESchering-Plough Research Institute, a division of Schering Corporation315
进行中（未招募）
1 期
Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice. - RE3Adult subjects with a diganosis of Rheumatoid Arthritis presenting with a disease flare after an initial response to infliximab.EUCTR2005-001889-13-GRIntegrated Therapeutics Group, Inc. - A subsidiary of Schering-Plough Corp.315
进行中（未招募）
不适用
Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice. - RE3Adult subjects with a diganosis of Rheumatoid Arthritis presenting with a disease flare after an initial response to infliximab.MedDRA version: 8.1Level: LLTClassification code 10060732Term: Rheumatoid arthritis flare upEUCTR2005-001889-13-DKIntegrated Therapeutics Group, Inc. - A subsidiary of Schering-Plough Corp.315
进行中（未招募）
不适用
Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice. - Re3Adult subjects with a diagnosis of Rheumatoid Arthritis presenting with a disease flare after an initial response to infliximabMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2005-001889-13-DESchering-Plough Research Institute (SPRI)315
进行中（未招募）
不适用
Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice. - RE3Adult subjects with a diganosis of Rheumatoid Arthritis presenting with a disease flare after an initial response to infliximab.EUCTR2005-001889-13-ATIntegrated Therapeutics Group, Inc. - A subsidiary of Schering-Plough Corp.315